NewsSource: EClinCloud Official Website Archive

Congratulations! EClinCloud Supports Simcere Pharmaceutical on Approval of Insomnia Drug Quviviq®

1 min readEClinCloud Editorial Team
Archive article cover: Congratulations! EClinCloud Supports Marketing Approval of Simcere Pharmaceutical's Insomnia Medication Keweike®

On June 20, 2025, Simcere Pharmaceutical (2096.HK) announced that Quviviq® (generic name: daridorexant hydrochloride tablets), an insomnia drug from its collaboration with Swiss company Idorsia, received marketing approval from the National Medical Products Administration (NMPA) for the treatment of adult patients with insomnia characterized by difficulty falling asleep and/or maintaining sleep, and is not controlled as a psychotropic drug.

 

国家药监局2025年6月药品批准证明文件送达信息  

Image source: Official website of the National Medical Products Administration (NMPA)

 

Quviviq®'s approval in China was primarily based on a randomized, double-blind, placebo-controlled, parallel-group, multicenter registrational Phase III clinical trial (NCT06010693), as well as efficacy and safety data from Idorsia's global clinical trials. The Phase III study in China was led by Professor Wang Yuping of Xuanwu Hospital, Capital Medical University, and enrolled a total of 206 patients with insomnia disorder.

As a long-term partner of Simcere Pharmaceutical, EClinCloud provided an integrated endpoint assessment solution covering the eCOA system, scale management, and rater training for this Phase III clinical trial conducted in China, providing important support for the efficient advancement of the trial.

EClinCloud extends its sincere congratulations on the successful approval of Keweike®. As a technology-enabling partner in innovative drug research and development, going forward we will continue to provide pharmaceutical companies with more reliable AI-enabled digital solutions, advancing the digital and intelligent transformation of clinical trials and accelerating the drug development process.